Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 95 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Coronary Syndromes (ACS) Clear all
Completed Phase 4 Interventional Results available

Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

NCT04668144
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome
Interventions
Cangrelor, Prasugrel
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional Results available

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

NCT00933400
View directory record Official record
Conditions
Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions
CT Coronary Angiography (CTCA), Traditional Strategy
Diagnostic Test · Procedure
Lead sponsor
American College of Radiology
Other
Eligibility
30 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

NCT02406677
View directory record Official record
Conditions
Cost Sharing, Acute Coronary Syndrome
Interventions
Study voucher card
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
11,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
271
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 224 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

NCT02271022
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Non-Interventional Study
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 21, 2026, 9:53 AM EDT
Recruiting Phase 3 Interventional

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

NCT05918861
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
186
States / cities
Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 21, 2026, 9:53 AM EDT
Not listed No phase listed Observational

Randomized Trial of Prehospital Tropin Levels in Acute Coronary Syndrome (ACS)

NCT00764205
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Not listed
Lead sponsor
Redmond Fire Department Medic One
Government
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
-Mobile Units in King County-, Washington
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Jul 21, 2026, 9:53 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

NCT00305162
View directory record Official record
Conditions
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
Interventions
Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomization
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
8,882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 21, 2026, 9:53 AM EDT
Recruiting Not applicable Interventional

Breaking Fasts Ahead of Cardiac Caths

NCT06996639
View directory record Official record
Conditions
Stable Angina (SA), Unstable Angina (UA), NSTEMI - Non-ST Segment Elevation MI
Interventions
Non-Fasting, Fasting
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

NCT01225562
View directory record Official record
Conditions
Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
Interventions
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
50 Years to 130 Years
Enrollment
21,379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
250
States / cities
Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 247 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Jul 21, 2026, 9:53 AM EDT
Terminated Not applicable Interventional Results available

ST Monitoring to Detect Acute Coronary Syndrome Events in Implantable Cardioverter Defibrillator Patients

NCT01424722
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Not applicable Interventional

Magnetocardiography (MCG) Device Use in Patients With Elevated Troponin

NCT06620744
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome
Interventions
Sponsor MCG deivce
Device
Lead sponsor
SB Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative

NCT01984853
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
OBSERVATIONAL REGISTRY
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

NCT02525939
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
dalcetrapib, Placebo
Drug
Lead sponsor
DalCor Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
6,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
122
States / cities
Alexander City, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Incident COronary EveNts Identified by Computed Tomography

NCT02959099
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 21, 2026, 9:53 AM EDT
Not listed No phase listed Observational

Validation of Simple Acute Coronary Syndrome (SACS) Score

NCT02358148
View directory record Official record
Conditions
Chest Pain, Acute Coronary Syndrome, Angina, Myocardial Infarction
Interventions
Not listed
Lead sponsor
Bayfront Health St Petersburg
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Dade City, Florida • St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jul 21, 2026, 9:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

NCT05323136
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome
Interventions
MT1002 for Injection
Drug
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 21, 2026, 9:53 AM EDT
Withdrawn Not applicable Interventional

Integrated Smoking Cessation and Mood Management for ACS Patients

NCT03029923
View directory record Official record
Conditions
Acute Coronary Syndrome, Tobacco Use
Interventions
Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS), Smoking cessation plus Health and Wellness
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 4 Interventional Results available

Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)

NCT00790907
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
3,235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Ocala, Florida • Albuquerque, New Mexico • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Jul 21, 2026, 9:53 AM EDT
Active, not recruiting Phase 2 Interventional

Online Tai Chi Plus Fitbit After ACS

NCT05699642
View directory record Official record
Conditions
Acute Coronary Syndrome, Physical Inactivity
Interventions
Tai chi + wearable
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Point of Care (POC) Biomarkers of Ischemia

NCT02039882
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Jul 21, 2026, 9:53 AM EDT
Completed Phase 3 Interventional

SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes

NCT00043784
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Myocardial Ischemia
Interventions
enoxaparin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2008 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational

Myeloperoxidase and Multi-Markers In the Diagnosis of Diagnoses of Acute Coronary Syndrome (MIDAS) - Sample Procurement

NCT00415948
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS)
Interventions
Biomarkers
Device
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Sacramento, California • New Haven, Connecticut • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2009 · Synced Jul 21, 2026, 9:53 AM EDT
Completed No phase listed Observational Results available

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

NCT01088503
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
ADP receptor inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
185
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Jul 21, 2026, 9:53 AM EDT